BOSTON, January 30, 2014—It may be possible one day to treat several lung diseases by introducing proteins that direct lung stem cells to grow the specific cell types needed to repair the lung injuries involved in the conditions, according to new research at Boston Children's Hospital.
Reporting in the January 30th issue of Cell, researchers led by Carla Kim, PhD, and Joo-Hyeon Lee, PhD, of the Stem Cell Research Program at Boston Children's, describe a new pathway in the lung, activated by injury, that directs stem cells to transform into specific types of cells. By enhancing this natural pathway in a mouse model, they successfully increased production of alveolar epithelial cells, which line the small sacs (alveoli) where gas exchange takes place. These cells are irreversibly damaged in diseases like pulmonary fibrosis and emphysema.
By inhibiting the same pathway, the researchers ramped up production of airway epithelial cells, which become damaged in diseases affecting the lung's airways, such as asthma and bronchiolitis obliterans.
Using a novel 3D culture model that mimics the environment of the lung, the researchers showed that even a single lung stem cell could be coaxed into producing alveolar and bronchiolar epithelial cells. By adding a protein known as thrombospondin-1 (TSP-1) to these cultures, they prodded the stem cells to generate alveolar cells.
Kim and Lee conducted experiments using a live mouse model of fibrosis. By simply taking the endothelial cells that line the lung's many small blood vessels—which naturally produce TSP-1—and directly injecting the liquid surrounding the cultured cells into the mice, they were able to reverse the lung damage.
Conversely, when the team used lung endothelial cells that lacked TSP-1 in the 3D cultures, the stem cells produced more airway cells. In live mice engineered to lack TSP-1, airway repair was enhanced after injury.
"When lung cells are injured, there seems to be a cross talk between the damaged cells, the lung endothelial cells and the stem cells," says Lee, who is first author on the paper.
"We think that lung endothelial cells produce a lot of repair factors besides TSP-1," adds Kim, the paper's senior author. "We want to find all these molecules, which could provide additional therapeutic targets."
The study was supported by the Hope Funds for Cancer Research, the National Heart, Lung and Blood Institute (U01 HL100402; 1U01HL099997; RFA-HL-09-004; RO1 HL090136), an American Cancer Society Research Scholar Grant (RSG-08-082-01-MGO), a Basil O'Conner March of Dimes Starter Award and the Harvard Stem Cell Institute.
Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 13 members of the Institute of Medicine and 14 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children's, visit: http://vectorblog.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.